A Phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease (PASADENA): rationale, design and baseline data
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
Qualified researchers may request access to individual patient-level data through the clinical study data request platform (https://vivli.org/). Further details on Roche's criteria for eligible studies are available here (http://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm). Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database (https://www.ppmi-info.org/data). For up-to-date information on the study, visit ppmi-info.org.
Subject Area
- Addiction Medicine (329)
- Allergy and Immunology (648)
- Anesthesia (174)
- Cardiovascular Medicine (2497)
- Dermatology (210)
- Emergency Medicine (385)
- Epidemiology (11968)
- Forensic Medicine (10)
- Gastroenterology (718)
- Genetic and Genomic Medicine (3892)
- Geriatric Medicine (360)
- Health Economics (652)
- Health Informatics (2514)
- Health Policy (970)
- Hematology (350)
- HIV/AIDS (813)
- Medical Education (386)
- Medical Ethics (106)
- Nephrology (415)
- Neurology (3650)
- Nursing (205)
- Nutrition (544)
- Oncology (1895)
- Ophthalmology (553)
- Orthopedics (230)
- Otolaryngology (299)
- Pain Medicine (240)
- Palliative Medicine (71)
- Pathology (461)
- Pediatrics (1070)
- Primary Care Research (434)
- Public and Global Health (6320)
- Radiology and Imaging (1338)
- Respiratory Medicine (845)
- Rheumatology (389)
- Sports Medicine (334)
- Surgery (426)
- Toxicology (51)
- Transplantation (179)
- Urology (154)